Amyloid-beta peptide–MHC class II complex

The **Amyloid-beta peptide–MHC class II complex** refers to the presentation of fragments of the amyloid-beta (Aβ) peptide, predominantly Aβ1–42 or Aβ1–40, by major histocompatibility complex class II (MHC-II) molecules on antigen-presenting cells such as dendritic cells, microglia, or macrophages. MHC-II molecules bind exogenously derived peptides (typically 12–25 amino acids long) in their open-ended peptide-binding groove and display them on the cell surface for recognition by CD4+ T cells[1][4]. In the context of Alzheimer's disease, Aβ peptides are taken up by antigen-presenting cells and can be loaded onto MHC-II, leading to the activation of helper T cell responses. This process may contribute to both protective immune surveillance and harmful neuroinflammation, depending on the balance of immune activity. The presence of this complex is a hallmark of immune system involvement in neurodegenerative disorders and is a subject of study for vaccine-based and immunomodulatory therapies for Alzheimer’s disease[5][6]. There are no approved drugs that directly target the Aβ–MHC-II complex, but strategies aimed at modulating this interaction (for example, tolerizing vaccines or cell therapies) are under experimental investigation. Additional notes: - This is a **composite target**, consisting of an endogenous peptide antigen and a presenting immune receptor. It is not a classical single-protein drug target, but rather a molecular interaction/complex central to immunological mechanisms in Alzheimer's disease. - At present, this target is mainly relevant for immunological studies, biomarker research, and experimental therapeutics in neurodegeneration, rather than conventional pharmacological targeting.

Other names

Amyloid-β peptide bound to major histocompatibility complex class IIAβ–MHC-II complexAmyloid-beta/MHC-II complex

Immunomodulation (therapeutics targeting this complex would aim to enhance, inhibit, or alter antigen-specific T cell activation) Vaccination or immune tolerance induction (in experimental settings for Alzheimer's disease)